Search
Filter Results
- Resource Type
- Journal2
- Journal Digital2
- Article1
- Article Type
- Clinical Trial1
- Randomized Controlled Trial1
- Clinical Study1
- Comparative Study1
- Result From
- Lane Catalog2
- PubMed1
-
Year
- Journal Title
- Acta Med Scand1
Search Results
Sort by
- JournalDigital Access ScienceDirect v. 1-8, 1972-89.
- JournalDigital Access ScienceDirect v. 1-8, 1972-89.
- ArticleBengtsson C.Acta Med Scand. 1976;199(1-2):65-70.Metoprolol, a new selective adrenergic beta1-receptor blocking drug, has been compared to placebo in a series of 24 women who previously had taken alprenolol and propranolol during a cross-over study. Blood pressure (BP) and heart rate (HR) were significantly reduced during metoprolol treatment compared to placebo. The occurrence of side-effects was similar during treatment with metoprolol and placebo. After the cross-over study the patients continued on metoprolol for more than two years, except for short periods on placebo or propranolol. During this follow-up period BP remained at a similar level when the metoprolol dose was unchanged. Dose reduction (from 50 or 100 mg t.i.d. to 50 or 100 mg b.i.d.) caused no, or only a very slight, increase in BP. No side-effects were reported during long-term treatment.